CA3092596C - Novel aminothiol reduction of ischemia-reperfusion-induced cell death - Google Patents
Novel aminothiol reduction of ischemia-reperfusion-induced cell death Download PDFInfo
- Publication number
- CA3092596C CA3092596C CA3092596A CA3092596A CA3092596C CA 3092596 C CA3092596 C CA 3092596C CA 3092596 A CA3092596 A CA 3092596A CA 3092596 A CA3092596 A CA 3092596A CA 3092596 C CA3092596 C CA 3092596C
- Authority
- CA
- Canada
- Prior art keywords
- prc
- compound
- organ
- use according
- reperfusion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/12—Chemical aspects of preservation
- A01N1/122—Preservation or perfusion media
- A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Environmental Sciences (AREA)
- Wood Science & Technology (AREA)
- Dentistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Biophysics (AREA)
- Physiology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862710838P | 2018-03-01 | 2018-03-01 | |
| US62/710,838 | 2018-03-01 | ||
| PCT/CN2019/070444 WO2019165851A1 (en) | 2018-03-01 | 2019-01-04 | Novel aminothiol reduction of ischemia-reperfusion-induced cell death |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA3092596A1 CA3092596A1 (en) | 2019-09-06 |
| CA3092596C true CA3092596C (en) | 2024-05-21 |
Family
ID=67805623
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3092596A Active CA3092596C (en) | 2018-03-01 | 2019-01-04 | Novel aminothiol reduction of ischemia-reperfusion-induced cell death |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11690813B2 (https=) |
| EP (2) | EP4588472A1 (https=) |
| JP (1) | JP7121418B2 (https=) |
| KR (1) | KR102490204B1 (https=) |
| CN (1) | CN111801095A (https=) |
| AU (1) | AU2019228134B2 (https=) |
| CA (1) | CA3092596C (https=) |
| WO (1) | WO2019165851A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022312709A1 (en) * | 2021-07-16 | 2024-01-18 | Obvia Pharmaceuticals Ltd. | Prc-210 for use in the treatment of acute tissue injury |
| WO2024168231A1 (en) * | 2023-02-10 | 2024-08-15 | Obvia Pharmaceuticals, Ltd. | Aminothiols for the treatment of conditions characterized by protein misfolding or aggregation, mitochondrial dysfunction, or chronic inflammation |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6031006A (en) | 1999-10-21 | 2000-02-29 | Bionumerik Pharmaceuticals, Inc. | Method of treating diabetic nephropathy |
| WO2005014524A2 (en) | 2003-08-07 | 2005-02-17 | Wisconsin Alumni Research Foundation | Amino thiol compounds and compositions for use in conjunction with cancer therapy |
| EP1788092A1 (en) * | 2004-07-30 | 2007-05-23 | Japan Science and Technology Agency | Method of inhibiting postischemic reperfusion-induced cell death and cell death inhibitor |
| WO2017004485A1 (en) * | 2015-07-02 | 2017-01-05 | Raptor Pharmaceuticals Inc. | Ado-resistant cysteamine analogs and uses thereof |
-
2019
- 2019-01-04 EP EP25151058.2A patent/EP4588472A1/en active Pending
- 2019-01-04 CA CA3092596A patent/CA3092596C/en active Active
- 2019-01-04 CN CN201980011285.XA patent/CN111801095A/zh active Pending
- 2019-01-04 US US16/629,851 patent/US11690813B2/en active Active
- 2019-01-04 WO PCT/CN2019/070444 patent/WO2019165851A1/en not_active Ceased
- 2019-01-04 JP JP2020554358A patent/JP7121418B2/ja active Active
- 2019-01-04 KR KR1020207026024A patent/KR102490204B1/ko active Active
- 2019-01-04 AU AU2019228134A patent/AU2019228134B2/en active Active
- 2019-01-04 EP EP19760716.1A patent/EP3758691A4/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP4588472A1 (en) | 2025-07-23 |
| AU2019228134A1 (en) | 2020-10-22 |
| CA3092596A1 (en) | 2019-09-06 |
| AU2019228134B2 (en) | 2022-03-03 |
| CN111801095A (zh) | 2020-10-20 |
| US20210299066A1 (en) | 2021-09-30 |
| JP2021506982A (ja) | 2021-02-22 |
| EP3758691A4 (en) | 2021-11-17 |
| KR102490204B1 (ko) | 2023-01-19 |
| US11690813B2 (en) | 2023-07-04 |
| JP7121418B2 (ja) | 2022-08-18 |
| WO2019165851A1 (en) | 2019-09-06 |
| EP3758691A1 (en) | 2021-01-06 |
| KR20200118851A (ko) | 2020-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mendes-Braz et al. | The current state of knowledge of hepatic ischemia‐reperfusion injury based on its study in experimental models | |
| AU2003232526B2 (en) | Organ arrest, protection, preservation and recovery | |
| US8268890B2 (en) | Method of treating ischemia/reperfusion injury with nitroxyl donors | |
| KR102655918B1 (ko) | 산소첨가된 콜레스테롤 술페이트 (ocs) 의 용도 | |
| US20020132220A1 (en) | Use of selectin antagonists in organ preservation solutions | |
| US20030039638A1 (en) | Carbon monoxide improves outcomes in tissue and organ transplants and suppresses apoptosis | |
| US6900178B2 (en) | Protection against ischemia and reperfusion injury | |
| DK2143429T3 (en) | Use of cilastatin for reducing the nephrotoxicity of various compounds | |
| US20180042873A1 (en) | Novel methods | |
| CA3092596C (en) | Novel aminothiol reduction of ischemia-reperfusion-induced cell death | |
| JP2017535546A5 (https=) | ||
| Maezono et al. | Alanine protects liver from injury caused by D‐galactosamine and CCl4 | |
| US5661188A (en) | Therapeutic uses for sodium 2-mercaptoethanesulphonate (mesna) | |
| US20080089947A1 (en) | Calcium Influx Inhibitors in the Treatment of Ischemia | |
| EP1444983A1 (en) | Agents for treating inflammatory bowel diseases | |
| RU2456678C1 (ru) | Способ профилактики и лечения последствий ишемического воздействия на печень | |
| HK40031657A (en) | Novel aminothiol reduction of ischemia-reperfusion-induced cell death | |
| CN1320922C (zh) | 基于用丙二烯氧合酶将脂质过氧化物酶消除的心脏保护疗法 | |
| JPH0952801A (ja) | 移植臓器保存剤 | |
| EP1839675A1 (en) | Novel method of protecting ischemic cardiopathy | |
| WO2019071171A1 (en) | Method of treating sickle cell disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20200831 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241216 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241216 Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241216 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251216 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251216 |